Therapeutic strategies for Shiga toxin-producing Escherichia coli infections

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 6, 2009, Pages 683-686

  Rogers, Trisha J ^a   Paton, James C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

'STARFISH'; ANTIINFECTIVE AGENT; C 9; LED 209; N PHENYL 4 [(PHENYLAMINO)THIOXOMETHYL]AMINO]BENZENESULFONAMIDE; PLACEBO; PROBIOTIC AGENT; SHIGA TOXIN; SUPER TWIG; SYNSORB PK; UNCLASSIFIED DRUG; CERAMIDE TRIHEXOSIDE; ESCHERICHIA COLI PROTEIN; GLOBOSIDE; GLOBOTRIHEXOSYLCERAMIDE; VIRULENCE FACTOR;

BACTERIAL TRANSMISSION; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TARGETING; ESCHERICHIA COLI INFECTION; FABRY DISEASE; FOOD CHAIN; GASTROINTESTINAL INFECTION; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TAY SACHS DISEASE; TREATMENT PLANNING; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HELA CELL; METABOLISM; MICROBIOLOGY; MOUSE; PATHOGENICITY; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GLOBOSIDES; HELA CELLS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MICE; RATS; SHIGA TOXIN; SHIGA-TOXIGENIC ESCHERICHIA COLI; TRIHEXOSYLCERAMIDES; VIRULENCE FACTORS;

EID: 70350445379     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.51     Document Type: Conference Paper

References (13)

1. Yamagami S, Motoki M, Kimura T et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184, 738-742 (2001). (Pubitemid 32826425)
2. Armstrong GD, Fodor E, Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthetized oligosaccharide sequences. J. Infect. Dis. 164, 1160-1167 (1991).
3. Trachtman H, Cnaan A, Christen E et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated haemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290, 1337-1344 (2003). (Pubitemid 37442630)
4. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 6, 265-270 (2000). (Pubitemid 30148617)
5. Paton JC, Rogers TJ, Morona R, Paton AW. Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli. Infect. Immun. 69(3), 1389-1393 (2001). (Pubitemid 32187585)
6. Kitov PI, Sadowska JM, Mulvey G et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669-672 (2000). (Pubitemid 30104009)
7. Mulvey GL, Marcato P, Kitov PI, Sadowska J, Bundle DR, Armstrong GD. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis. 187, 640-649 (2003). (Pubitemid 36250028)
8. Nishikawa K, Matsuoka K, Kita E et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl Acad. Sci. USA 99, 7669-7674 (2002). (Pubitemid 34568749)
9. Silberstein C, Copeland DP, Chiang W-L, Repetto HA, Ibarra C. A glucosylceramide synthase inhibitor prevents the cytotoxic effects of Shiga toxin-2 on human renal tubular epithelial cells. J. Epith. Biol. Pharmacol. 1, 71-75 (2008).
10. Silberstein C, Lucero MS, Zotta E, Repetto H, Ibarra C. Effects of a glucosylceramide synthase inhibitor on an experimental model of haemolytic uremic syndrome in rats. Presented at: 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina, 10-13 May 2009.
11. Rasko DA, Moreira CG, Li DR et al. Targeting QseC signalling and virulence for antibiotic development. Science 321, 1078-1080 (2008).
12. Sperandio V. Inter-kingdom signalling in EHEC pathogenesis. Presented at: 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina, 10-13 May 2009.
13. Larzabal M, Vilte D, Mercado E, Salazar H, Navaro Garcia F, Cataldi A. Peptides inhibiting the type three secretion system (TTSS) from enteropathogenic and enterohemorrhagic Escherichia coli. Presented at: 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina, 10-13 May 2009.